Literature DB >> 30631555

Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

Shigeki Nanjo1,2, Trever G Bivona1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30631555      PMCID： PMC6297447          DOI： 10.21037/jtd.2018.09.106

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   3.005


× No keyword cloud information.
  25 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

Review 3.  Liquid biopsy: monitoring cancer-genetics in the blood.

Authors:  Emily Crowley; Federica Di Nicolantonio; Fotios Loupakis; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2013-07-09       Impact factor: 66.675

4.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

5.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

Authors:  Martin L Sos; Mirjam Koker; Barbara A Weir; Stefanie Heynck; Rosalia Rabinovsky; Thomas Zander; Jens M Seeger; Jonathan Weiss; Florian Fischer; Peter Frommolt; Kathrin Michel; Martin Peifer; Craig Mermel; Luc Girard; Michael Peyton; Adi F Gazdar; John D Minna; Levi A Garraway; Hamid Kashkar; William Pao; Matthew Meyerson; Roman K Thomas
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Authors:  Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

9.  Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.

Authors:  Yoji Kukita; Junji Uchida; Shigeyuki Oba; Kazumi Nishino; Toru Kumagai; Kazuya Taniguchi; Takako Okuyama; Fumio Imamura; Kikuya Kato
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

10.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

Authors:  Aaron M Newman; Scott V Bratman; Jacqueline To; Jacob F Wynne; Neville C W Eclov; Leslie A Modlin; Chih Long Liu; Joel W Neal; Heather A Wakelee; Robert E Merritt; Joseph B Shrager; Billy W Loo; Ash A Alizadeh; Maximilian Diehn
Journal:  Nat Med       Date:  2014-04-06       Impact factor: 53.440
View more
  1 in total

1.  Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?

Authors:  In-Jae Oh
Journal:  Transl Lung Cancer Res       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.